Par Pharma Says Its New Drug Won't Rip Off GSK's Lamictal
Par Pharmaceutical Inc. on Wednesday urged a Pennsylvania federal court to declare that its new drug doesn't infringe GlaxoSmithKline LLC's epilepsy and bipolar disorder treatment Lamictal, saying the U.S. Food and...To view the full article, register now.
Already a subscriber? Click here to view full article